![logo](/logos/ALT.webp)
Altimmune, Inc.
NASDAQ:ALT
6.2 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Altimmune, Inc. |
Symbool | ALT |
Munteenheid | USD |
Prijs | 6.2 |
Beurswaarde | 440,639,580 |
Dividendpercentage | 0% |
52-weken bereik | 2.09 - 14.84 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Vipin K. Garg Ph.D. |
Website | https://altimmune.com |
An error occurred while fetching data.
Over Altimmune, Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)